Biopharmx Corp (NYSE:BPMX) was the target of a significant increase in short interest in the month of September. As of September 29th, there was short interest totalling 4,147,107 shares, an increase of 2.1% from the September 15th total of 4,060,605 shares. Currently, 7.2% of the shares of the company are short sold. Based on an average trading volume of 1,362,369 shares, the days-to-cover ratio is presently 3.0 days.

Shares of Biopharmx Corp (BPMX) traded up 2.456% on Tuesday, hitting $0.292. 3,914,050 shares of the stock were exchanged. The firm’s 50 day moving average price is $0.30 and its 200 day moving average price is $0.46. The firm’s market cap is $23.26 million. Biopharmx Corp has a one year low of $0.19 and a one year high of $0.90.

WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/10/biopharmx-corp-bpmx-short-interest-update-3.html.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.